Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades Applied Genetic Techs to Neutral

HC Wainwright & Co. Downgrades Applied Genetic Techs to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Applied Genetic Techs (NASDAQ:AGTC) from Buy to Neutral.

byBenzinga Newsdesk

October 25, 2022

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis downgrades Applied Genetic Techs (NASDAQ:AGTC) from Buy to Neutral.

Digital Brands Gains On Solid FY23 Guidance

By Shivani Kumaresan

January 11, 3:20 PM

Digital Brands Group Inc (NASDAQ:DBGI) expects FY23 revenue of $45 million – $50 million. The company sees FY23 EBITDA of…

DBGI

Truist Securities Maintains Sell on Carnival, Raises Price Target to $10

By Benzinga Newsdesk

September 20, 7:36 AM

Truist Securities analyst Patrick Scholes maintains Carnival (NYSE:CCL) with a Sell and raises the price target from $8 to $10.

CCL

News

Why NIO Stock Hit A New 52-Week Low Today

By Henry Khederian

May 2, 1:57 PM

NIO Inc - ADR (NYSE: NIO) shares are trading lower by 5.06% to $7.42 Tuesday afternoon. Shares of several Chinese companies are trading lower following weak China manufacturing data.

NIO

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

By Vandana Singh

May 16, 12:35 PM

Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.

JNJ

HC Wainwright & Co. Downgrades Applied Genetic Techs to Neutral

Related Posts

Digital Brands Gains On Solid FY23 Guidance

Truist Securities Maintains Sell on Carnival, Raises Price Target to $10

Why NIO Stock Hit A New 52-Week Low Today

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M